Aclaris Therapeutics (ACRS) reported Q4 Revenue
Tweet
Share
E-mailGet Alerts ACRS Hot Sheet
Join SI Premium – FREE
Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 Revenue for the quarter came in at $9.21 million versus the consensus estimate of $2.08 million.
For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aytu BioScience (AYTU) Tops Q4 EPS by 28c
- JPMorgan Reiterates Overweight Rating on Dixon Technologies India Ltd (DIXON:IN)
- AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
